This meta-analysis was associated with the results of two clinical trials that evaluated the risk of cardiovascular diseases and benefits for the quality of life of patients with chronic kidney failure receiving EPO, the CHOIR and CREATE study [152,153]. The gene discussed is EPO; the disease is chronic renal failure syndrome.